BRAF and cancer: Moreover, BRAF mutated colorectal cancers with or without PIK3CA mutations, as well as PIK3CA mutated cancers without BRAF mutations possess lower mutation rates of TP53, suggesting that activation of either or both oncogenes decrease pressure for disabling of TP53 in colorectal cancer cells.